Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. Patient summary: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions. The EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guidelines panel recommends stratifying patients experiencing biochemical recurrence (BCR) after primary treatment for localized prostate cancer into EAU low-risk and high-risk BCR groups. Each patient's risk profile and life expectancy should be considered when discussing the benefits and toxicities of salvage treatments.

Additional Metadata
Keywords Biochemical recurrence, European Association of Urology, Gleason score, Guidelines, Prognostic factors, Prostate cancer, PSA kinetics, Radical prostatectomy, Radiotherapy
Persistent URL,
Journal European Urology Focus
van den Broeck, T, van den Bergh, R.C.N, Briers, E, Cornford, P, Cumberbatch, M. (Marcus), Tilki, D. (Derya), … Mottet, N. (2019). Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. European Urology Focus, In Press, Corrected Proof. doi:10.1016/j.euf.2019.06.004